MedTrace Logo

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01458340 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 295

Last updated 2022-04-04

Study results available
· View outcomes & findings →

Summary

The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.

Conditions

  • Attention-Deficit/Hyperactivity Disorder
  • ADHD

Interventions

DRUG

TD-9855

Once daily

DRUG

TD-9855

Once daily

DRUG

Placebo

Once daily

Sponsors & Collaborators

  • Theravance Biopharma

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Theravance Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458340 on ClinicalTrials.gov